A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

BACKGROUND. Sorafenib has proven survival benefits in patients with advanced hepatocellular carcinoma (HCC). The viability of continuing sorafenib at a higher dosage in patients who experienced radiologic disease progression was investigated. METHODS. Patients who experienced disease progression whi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Rimassa, Lorenza, Pressiani, Tiziana, Boni, Corrado, Carnaghi, Carlo, Rota Caremoli, Elena, Fagiuoli, Stefano, Foa, Paolo, Salvagni, Stefania, Cortesi, Enrico, Chiara Tronconi, Maria, Personeni, Nicola, Bozzarelli, Silvia, Chiara Banzi, Maria, Fanello, Silvia, Romano Lutman, Fabio, Giordano, Laura, Santoro, Armando
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2013
Soggetti:
Clinical Trial Results
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3639524/
https://ncbi.nlm.nih.gov/pubmed/23580239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0221
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi